Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ception Therapeutics Inc.

Division of Teva Pharmaceutical Industries Ltd.
www.ceptiontx.com

Latest From AB Science

EU CHMP Decides On New Oncology Drugs & New Treatments for Mastocytosis, Atopic Dermatitis

The European Medicines Agency’s key scientific committee, the CHMP, is deciding this week whether a dozen or so new medicines that are in the final stages of the evaluation process should be approved for marketing across the EU. The committee will discuss 13 initial marketing authorization applications.

Approvals Regulation

Pulled From EU Assessment Process: Orphan Drugs For Kidney Disease, Mesothelioma

Two orphan medicines have been withdrawn from the evaluation process at the European Medicines Agency, one of them for recurrent nephrotic syndrome, the other for mesothelioma. Three products are undergoing a re-evaluation after an initial negative opinion from the CHMP.

Drug Review Europe

Janssen's Zytiga Shines At ASCO But Prostate Cancer Pipeline Progress May Dampen Impact

Janssen reported treatment altering Phase III data at ASCO 2017 for a new Zytiga combination targeting hormone-naïve metastatic prostate cancer patients – but the triple regimen's relevance might be short-lived as momentum builds in the late-stage pipeline.

Clinical Trials Cancer

Pipeline Watch: Top-Line Lanadelumab, Inotersen, Durvalumab Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Teva Pharmaceutical Industries Ltd.
  • Senior Management
  • Stephen Tullman, Pres. & CEO
    Doug Gessl, CFO
    Tim Henkel, MD, PhD, EVP, R&D
  • Contact Info
  • Ception Therapeutics Inc.
    Phone: (610) 640-2940
    101 Lindenwood Dr., Ste. 400
    Malvern, PA 19355
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register